LAV

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

2026年3月17日

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of...

Ronovo Surgical advances commercialization in China through Targeted Collaboration Agreement with Johnson & Johnson

2025年9月6日

Shanghai, China – September 5, 2025 – Ronovo Surgical, a global innovator in next-generation...

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

2025年4月11日

Shanghai, China, April 10, 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced...

Syneron Bio Announces Strategic Collaboration with AstraZeneca

2025年3月21日

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug...

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

2025年1月17日

SHANGHAI, January 16th, 2025 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

2025年1月13日

[January 13, 2025] – Cornerstone Robotics (the “Company”), a leading global innovator in surgical...

Alebund Pharmaceutical announced the first closing of RMB 550 million in Series C financing

2025年1月7日

January 7, 2025, Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated...

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2024年12月18日

MIAMI--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today...

AGAMREE® for DMD Treatment was Approved by China’s NMPA

2024年12月11日

December 11, 2024, Sperogenix Therapeutics announced that, AGAMREE® (vamorolone) was approved by...

Duality Biologics and GSK Enter into Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

2024年12月4日

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics (...

IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

2024年11月15日

SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

2024年10月29日

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B...

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

2024年9月30日

Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered...

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

2024年8月2日

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ...

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

2024年7月19日

- Financing led by LongRiver Investments with participation by new and existing global...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

2024年6月13日

- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

2024年5月16日

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to...

The Phase 3 clinical trial data of Senaparib published in Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

2024年5月15日

On May 15, 2024, the internationally renowned medical journal Nature Medicine (Latest impact...

Impact Raises RMB 400 million in Series D+ Funding

2024年4月19日

SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

2024年4月4日

Genmab to acquire ProfoundBio for USD 1.8 billion in cashAcquisition will give Genmab...

All Categories - LAV